Get the Stockscreener App
3.63
6.92%
-0.27
Trisalus Life Sciences Inc stock is traded at $3.63, with a volume of 253.52K.
It is down -6.92% in the last 24 hours and down -26.37% over the past month.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
See More
Previous Close:
$3.90
Open:
$3.83
24h Volume:
253.52K
Relative Volume:
1.46
Market Cap:
$223.52M
Revenue:
$45.15M
Net Income/Loss:
$-39.23M
P/E Ratio:
-1.9847
EPS:
-1.829
Net Cash Flow:
$-18.93M
1W Performance:
-10.59%
1M Performance:
-26.37%
6M Performance:
-19.15%
1Y Performance:
-23.58%
1-Day Range:
$3.58
$3.90
1-Week Range:
$3.58
$4.15
52-Week Range:
$2.20
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
3.63 | 223.52M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-26 | Initiated | H.C. Wainwright | Buy |
| Feb-13-25 | Initiated | Lake Street | Buy |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
View All
Trisalus Life Sciences Inc Stock (TLSI) Latest News
TriSalus Life Sciences (TLSI) regulatory chief sells 316 shares to cover stock-vesting taxes - Stock Titan
296 shares sold for taxes: TriSalus Life Sciences (TLSI) research chief's sale was not discretionary. - Stock Titan
A sale to cover vesting taxes, not a discretionary trade: TriSalus Life Sciences (TLSI) insider sells 325 shares. - Stock Titan
TriSalus Life Sciences Warrant (TLSIW) Eases 2.35% to $0.83 as Traders Watch the $0.79 Support ZoneVolatility Smirk - dars.gov.et
TriSalus Life Sciences Warrant (TLSIW) Trades Flat at $0.85 as Traders Eye a Narrow RangeHigh Yield Stocks - https://www.siam.in/
Postmarket Movers: IPDN, SDA, JAGX Lead After-Hours Gainers; BMEA, EPSM, PFSA Lead Losers - ChartMill
TriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav Advance - marketscreener.com
Crude Oil Gains 1%; Cintas Earnings Top Views - benzinga.com
Gap-Up and Gap-Down Stocks: Sept. 23, 2026 Session - ChartMill
Gap-Up and Gap-Down Stocks: Sept. 23, 2026 Session - ChartMill
H.C. Wainwright raises TriSalus stock price target on FDA approval - Investing.com
H.C. Wainwright raises TriSalus stock price target on FDA approval By Investing.com - Investing.com Nigeria
Why is TriSalus Life Sciences stock surging today? - Investing.com
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket - Benzinga
TriSalus Life shares surge 29% on FDA device clearance By Investing.com - Investing.com South Africa
These stocks are moving in today's after hours session - ChartMill
FDA clears a device for smaller blood vessels. TriSalus made it. - Stock Titan
Postmarket Movers: IPDN, SDA, JAGX Lead After-Hours Gainers; BMEA, EPSM, PFSA Lead Losers - ChartMill
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
TriSalus Life Sciences (TLSI) Climbs 1.55% as Support Holds Above $4.99Wyckoff Distribution - vinanet.vn
TriSalus Life Sciences (TLSI) Climbs 1.55% as Support Holds Above $4.99Sentiment Divergence - siam.in
TriSalus Life Sciences (TLSI) Climbs 1.55% as Support Holds Above $4.99Fibonacci Time Zone - careplusvn.com
TriSalus Life Sciences (TLSI) Climbs 1.55% as Support Holds Above $4.99Blue Chip Entry Points - dars.gov.et
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference - Business Wire
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference - Yahoo Finance
TriSalus Life Sciences (TLSI) Slips 2% as Shares Test Key $4.59 Support LevelKey Reversal Day - dars.gov.et
TriSalus Life Sciences (TLSI) Slips 2% as Shares Test Key $4.59 Support LevelPrice Momentum Stocks - siam.in
TriSalus (TLSI) Results Review: The Bottom-Line Figure Trails Its Comparison in the Available Record; Share Response: Shares Move 3.04% Lower in the Latest SessionWeak Earnings Momentum - vinanet.vn
TriSalus (TLSI) Market: Falls 2.18% to $5.16 on the Day; Technical Setup: the Near-Term Reference Band Stretches From $4.90 to $5.42 on the DayETF NAV Deviation - vinanet.vn
TriSalus (TLSI) Latest: Finishes 1.90% Lower at $5.17 at the Close; Next Test: the Near-Term Reference Band Stretches From $4.91 to $5.43ETF Premium Discount - vinanet.vn
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates - Eastern Progress
TriSalus (TLSI) Latest Quarter: The Bottom-Line Figure Trails Its Comparison for This Review; Price Move: Shares Finish 2.47% Up in the Current UpdateSegment Revenue Breakdown - vinanet.vn
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street Zen - MarketBeat
TriSalus Life Sciences Warrant (TLSIW) Plunges 55%: Critical Support Test at $0.53AAII Bullish - vinanet.vn
TriSalus Life Sciences Warrant (TLSIW) Plunges 55%: Critical Support Test at $0.53Put Call Ratio - dars.gov.et
TriSalus Life Sciences Warrant (TLSIW) Plunges 55%: Critical Support Test at $0.53Overnight Profile - dars.gov.et
TriSalus Life Sciences Warrant (TLSIW) Plunges 55%: Critical Support Test at $0.53Fund Manager Survey - careplusvn.com
CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Trisalus Life Sciences at Canaccord Genuity: growth bets build By Investing.com - Investing.com Nigeria
Trisalus Life Sciences at Canaccord Genuity: growth bets build - Investing.com
TriSalus Life Sciences (TLSI) Advances 2.87% as Shares Hold Above $5.45 SupportETH Profile - dars.gov.et
Maxim Group Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Raises Target Price to $14 - Moomoo
TriSalus Life Sciences (TLSI) Advances 2.96% to $5.75 as Biotech Momentum BuildsMA Cross Alert - careplusvn.com
TLSI Q2 2026 Earnings: EPS Misses Slightly as Liver-Tumor Focus ContinuesEarnings Revision Downgrade - careplusvn.com
TLSI Q2 2026 Earnings: EPS Misses Slightly as Liver-Tumor Focus ContinuesRetail Earnings Report - vinanet.vn
TriSalus Life Sciences (TLSI) Dips 4.3% to $5.37 as Shares Approach Key Support ZonePut Spread Alert - vinanet.vn
TriSalus Life Sciences earnings missed by $0.01, revenue topped estimates - Investing.com Canada
TriSalus Life Sciences (TLSI) Stock Surges As Losses Deepen Behind Strong Margins - Sahm
TriSalus Life Sciences (TLSI) Stock Surges As Losses Deepen Behind Strong Margins - simplywall.st
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Trisalus Life Sciences Inc Stock (TLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stevens Jennifer | Chief Regulatory Officer |
Oct 05 '26 |
Sale |
4.39 |
316 |
1,387 |
123,794 |
| Marshak Richard | Chief Commercial Officer |
Oct 05 '26 |
Sale |
4.39 |
325 |
1,427 |
127,994 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
410,000 |
1,025,000 |
1,240,722 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
200,000 |
500,000 |
399,698 |
| Patience David | Chief Financial Officer |
May 15 '26 |
Buy |
2.43 |
7,100 |
17,253 |
275,757 |
| Wahlstrom Mats | Director |
May 15 '26 |
Buy |
2.53 |
60,000 |
151,800 |
147,555 |
| Marshak Richard | Chief Commercial Officer |
May 15 '26 |
Sale |
2.67 |
543 |
1,450 |
125,101 |
| Gordon Gary B. | Director |
May 15 '26 |
Buy |
2.46 |
10,000 |
24,600 |
72,510 |
| Szela Mary T | CEO and President |
May 15 '26 |
Buy |
2.59 |
39,682 |
102,776 |
1,065,215 |
| Szela Mary T | CEO and President |
Mar 17 '26 |
Sale |
3.85 |
15,944 |
61,384 |
752,987 |
2.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):